Antisense & RNAi Therapeutics Market by Technology, Route of Administration, Application, End User - Global Forecast 2025-2030- Product Image

Sale

Antisense & RNAi Therapeutics Market by Technology, Route of Administration, Application, End User - Global Forecast 2025-2030

Report
185 Pages
October 2024
Region: Global
360iResearch™
ID: 5887255

UP TO €688EUR$697USD£574GBP OFF until Dec 31^st 2024

The Antisense & RNAi Therapeutics Market grew from USD 4.43 billion in 2023 to USD 5.07 billion in 2024. It is expected to continue growing at a CAGR of 14.64%, reaching USD 11.54 billion by 2030.

Antisense and RNA interference (RNAi) therapeutics represent a burgeoning segment in biotechnology, focusing on altering RNA to inhibit the expression of specific genes. Their scope is vast, targeting genetic disorders, cancers, viral infections, and neurological diseases. These therapies are necessary due to their high specificity and ability to tackle traditionally "undruggable" targets. The application primarily lies in personalized medicine, leveraging genetic information to tailor treatments effectively. End-use sectors include pharmaceutical and biotechnology companies, research institutes, and hospitals. Market growth is driven by advancements in genetic sequencing, increased prevalence of chronic diseases, and growing investment in precision medicine. North America leads the market, bolstered by a robust healthcare infrastructure and significant R&D funding, while Europe and Asia-Pacific also show substantial growth potential.

Key opportunities in this market include expanding use in rare diseases, strategic collaborations for drug development, and technological advancements in delivery mechanisms. Companies can leverage partnerships with academic institutions to accelerate research and innovation pipelines. However, challenges persist, such as high development costs, stringent regulatory landscapes, and potential off-target effects or immune responses. The intricate mechanisms of RNA-based therapies require sophisticated delivery vectors, posing another significant hurdle. Innovation should focus on improving delivery systems, enhancing stability and efficacy of oligonucleotides, and integrating AI for drug discovery and patient stratification. Developing biodegradable and less toxic delivery nanoparticles or exosomes could further enhance therapeutic outcomes.

The market is dynamic, with a strong tilt towards innovation and strategic collaborations. Constantly evolving regulatory policies necessitate adaptive strategies. For businesses aiming to lead, investment in understanding gene expression and molecular biology is crucial. As the landscape shifts, capturing market share will depend on a company's ability to quickly integrate new technologies, navigate regulatory challenges, and address unmet medical needs. Future growth hinges on breakthroughs in delivery technologies and further lowering the costs of RNA-based therapies to reach broader populations.

Understanding Market Dynamics in the Antisense & RNAi Therapeutics Market

The Antisense & RNAi Therapeutics Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Increasing prevalence of genetic disorders worldwide
- Rise in R&D activities on antisense and RNAi-based therapies
Market Restraints
- High cost of manufacturing antisense-RNAi-therapeutics
Market Opportunities
- Collaboration between biotech companies and academic institutions accelerates for antisense & RNAi therapeutics research
- Rising awareness about personalized medicine
Market Challenges
- Concerns associated with the efficacy of antisense-RNAi-therapeutics

Exploring Porter’s Five Forces for the Antisense & RNAi Therapeutics Market

Porter’s Five Forces framework further strengthens the insights of the Antisense & RNAi Therapeutics Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Antisense & RNAi Therapeutics Market

External macro-environmental factors deeply influence the performance of the Antisense & RNAi Therapeutics Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Antisense & RNAi Therapeutics Market

The Antisense & RNAi Therapeutics Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Antisense & RNAi Therapeutics Market

The Antisense & RNAi Therapeutics Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Antisense & RNAi Therapeutics Market

The Antisense & RNAi Therapeutics Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antisense & RNAi Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., Amarna Therapeutics BV, Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Inc., AstraZeneca plc, Benitec Biopharma Limited, Carisma Therapeutics Inc., Evox Therapeutics Ltd, GenScript Biotech Corporation, Ionis Pharmaceuticals, Inc., Novo Nordisk A/S, Regenxbio Inc., Sanofi S.A., Silence Therapeutics plc, Sirnaomics, Inc., Viridian Therapeutics, Inc., and Wave Life Sciences Ltd.

Market Segmentation & Coverage

This research report categorizes the Antisense & RNAi Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Technology
- Antisense RNA
- RNA Interference
  - miRNA
  - siRNA
Route of Administration
- Intra-dermal Injections
- Intraperitoneal Injections
- Intravenous Injections
- Pulmonary Delivery
- Topical Delivery
Application
- Cardiovascular Diseases (CVDs)
- Genetic Disorders
- Infectious Diseases
- Neurodegenerative Disorders
- Oncology
- Renal Diseases
- Respiratory Disorders
End User
- Hospitals:
- Pharmaceutical & Biotechnology Companies
- Research & Academic Institutes
- Specialty Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of genetic disorders worldwide
5.1.1.2. Rise in R&D activities on antisense and RNAi-based therapies
5.1.2. Restraints
5.1.2.1. High cost of manufacturing antisense-RNAi-therapeutics
5.1.3. Opportunities
5.1.3.1. Collaboration between biotech companies and academic institutions accelerates for antisense & RNAi therapeutics research
5.1.3.2. Rising awareness about personalized medicine
5.1.4. Challenges
5.1.4.1. Concerns associated with the efficacy of antisense-RNAi-therapeutics
5.2. Market Segmentation Analysis
5.2.1. Technology: increasing adoption of RNA interference owing to precise genetic targeting
5.2.2. Application: Boosting applications of antisense & RNAi therapeutics in oncology due to targeting cancer-specific mutations
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Antisense & RNAi Therapeutics Market, by Technology

6.1. Introduction
6.2. Antisense RNA
6.3. RNA Interference
6.3.1. miRNA
6.3.2. siRNA

7. Antisense & RNAi Therapeutics Market, by Route of Administration

7.1. Introduction
7.2. Intra-dermal Injections
7.3. Intraperitoneal Injections
7.4. Intravenous Injections
7.5. Pulmonary Delivery
7.6. Topical Delivery

8. Antisense & RNAi Therapeutics Market, by Application

8.1. Introduction
8.2. Cardiovascular Diseases (CVDs)
8.3. Genetic Disorders
8.4. Infectious Diseases
8.5. Neurodegenerative Disorders
8.6. Oncology
8.7. Renal Diseases
8.8. Respiratory Disorders

9. Antisense & RNAi Therapeutics Market, by End User

9.1. Introduction
9.2. Hospitals:
9.3. Pharmaceutical & Biotechnology Companies
9.4. Research & Academic Institutes
9.5. Specialty Clinics

10. Americas Antisense & RNAi Therapeutics Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Antisense & RNAi Therapeutics Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Antisense & RNAi Therapeutics Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. Sirnaomics Ltd. showcased innovative galAhead muRNA technology at the 2024 OPT congress in Boston
13.3.2. Ribocure Pharmaceuticals AB and Boehringer Ingelheim International GmbH partner to develop innovative RNAi-based treatments
13.3.3. Shanghai Argo Biopharmaceutical Co., Ltd. partnered with Novartis AG in a Landmark USD 4.165 Billion deal to advance RNAi therapeutics for cardiovascular diseases
13.4. Strategy Analysis & Recommendation

List of Figures

FIGURE 1. ANTISENSE & RNAI THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. ANTISENSE & RNAI THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. ANTISENSE & RNAI THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. ANTISENSE & RNAI THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ANTISENSE & RNAI THERAPEUTICS MARKET DYNAMICS
TABLE 7. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE RNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MIRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SIRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRA-DERMAL INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAPERITONEAL INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PULMONARY DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES (CVDS), BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RENAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY HOSPITALS:, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 49. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 50. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 52. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 54. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 55. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 57. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 74. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 76. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 77. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 79. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 81. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 82. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 86. INDONESIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 87. INDONESIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. INDONESIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. INDONESIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 91. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 92. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 94. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. MALAYSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 96. MALAYSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 97. MALAYSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. MALAYSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. MALAYSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. PHILIPPINES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 101. PHILIPPINES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 102. PHILIPPINES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. PHILIPPINES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. PHILIPPINES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. SINGAPORE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 106. SINGAPORE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 107. SINGAPORE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. SINGAPORE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 109. SINGAPORE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 111. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 112. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 114. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. TAIWAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 116. TAIWAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 117. TAIWAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. TAIWAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. TAIWAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. THAILAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 121. THAILAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 122. THAILAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. THAILAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 124. THAILAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. VIETNAM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 126. VIETNAM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 127. VIETNAM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. VIETNAM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. VIETNAM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 136. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 137. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 138. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 140. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 142. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 143. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 145. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 147. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 148. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 150. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 152. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 153. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 155. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 157. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 158. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 160. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. ISRAEL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 162. ISRAEL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 163. ISRAEL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. ISRAEL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 165. ISRAEL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 167. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 168. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 170. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 177. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 178. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 180. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. NORWAY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 182. NORWAY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 183. NORWAY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. NORWAY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 185. NORWAY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. POLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 187. POLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 188. POLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. POLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 190. POLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 192. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 193. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 195. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 200. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 210. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 212. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 213. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 215. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 217. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 218. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 220. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 223. SWITZERLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 225. SWITZERLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 227. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 228. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 230. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
TABLE 238. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 240. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. ANTISENSE & RNAI THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 242. ANTISENSE & RNAI THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Antisense & RNAi Therapeutics Market, which are profiled in this report, include:

Alnylam Pharmaceuticals, Inc.
Amarna Therapeutics BV
Arbutus Biopharma Corporation
Arrowhead Pharmaceuticals, Inc.
AstraZeneca plc
Benitec Biopharma Limited
Carisma Therapeutics Inc.
Evox Therapeutics Ltd
GenScript Biotech Corporation
Ionis Pharmaceuticals, Inc.
Novo Nordisk A/S
Regenxbio Inc.
Sanofi S.A.
Silence Therapeutics plc
Sirnaomics, Inc.
Viridian Therapeutics, Inc.
Wave Life Sciences Ltd

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	185
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 5.07 Billion
Forecasted Market Value ( USD ) by 2030	$ 11.54 Billion
Compound Annual Growth Rate	14.6%
Regions Covered	Global
No. of Companies Mentioned	17

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3502EUR$3,545USD£2,918GBP €3891EUR$3,939USD£3,243GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6195EUR$6,272USD£5,163GBP €6883EUR$6,969USD£5,737GBP

Understanding Market Dynamics in the Antisense & RNAi Therapeutics Market

Exploring Porter’s Five Forces for the Antisense & RNAi Therapeutics Market

Applying PESTLE Analysis to the Antisense & RNAi Therapeutics Market

Analyzing Market Share in the Antisense & RNAi Therapeutics Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Antisense & RNAi Therapeutics Market

Strategic Recommendations for Success in the Antisense & RNAi Therapeutics Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Antisense And RNAi Therapeutics Market Size, Share & Trends Analysis Report By Technology (RNA Interference, Antisense RNA), By Application (Ocular, Genetic), By Route of Administration (Intrathecal, Intravenous), By Region, And Segment Forecasts, 2024 - 2030

Antisense & RNAi Therapeutics Global Market Report 2024

Antisense and RNAi Therapeutics Market

Antisense & RNAi Therapeutics Market Report by Technology, and Region 2024-2032

Antisense & RNAi Therapeutics - A Global Market Overview